Other than female sex, no factors predict development of long-lasting symptoms<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 15, 2023 (HealthDay News) — More than half of cancer patients diagnosed with COVID-19 report postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) that may persist beyond six months, according to a study published online Feb. 7 in eLife<\/em>.<\/p>\n Hiba Dagher, M.D., from University of Texas MD Anderson Cancer Center in Houston, and colleagues assessed PASC in cancer patients following acute COVID-19 recovery. The analysis included data from 312 cancer patients followed for up to 14 months after COVID-19 infection.<\/p>\n The researchers found that 60 percent of patients reported long COVID symptoms, with a median duration of seven months after COVID-19 diagnosis. Fatigue (82 percent), sleep disturbances (78 percent), myalgias (67 percent), and gastrointestinal symptoms (61 percent) were the most common complaints, followed by headache (47%), altered smell or taste (47%), dyspnea (47 percent), and cough (46 percent). More women reported persistent symptoms than men (63 versus 37 percent). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease did not differ between those with long COVID symptoms and those without. A minority of patients with PASC (8.5 percent) were readmitted for COVID-19-related reasons.<\/p>\n “Besides the female gender, we found no other underlying condition or severity of illness during acute COVID-19 that would predict PASC,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n